Performance status-2 - Symptomatic, 50 in bed - Page 12 of 12 Posts on Medivizor
Navigation Menu

Performance status-2 – Symptomatic, 50 in bed Posts on Medivizor

Oxaliplatin improves survival in different groups of patients with stage III colon cancer.

Oxaliplatin improves survival in different groups of patients with stage III colon cancer.

Posted by on Feb 24, 2013 in Colorectal cancer | 0 comments

In a nutshell The present article compared survival rates of adjuvant chemotherapy regimens with and without Oxaliplatin in patients with stage III colon cancer. This article shows that Oxaliplatin improved survival in large clinical trials.  Some background Treatment for patients with stage III colon cancer consists of surgery to...

Read More

Comparing the benefits of two drug combinations as adjuvant chemotherapy for patients with stage III colon cancer

Posted by on Feb 24, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study compared the survival benefits of two drug combinations used for adjuvant chemotherapy: Capecitabine/Oxaliplatin (Xelox) versus Fluorouracil/Folinic Acid (FU/FA). The study found Xelox to be a superior therapy for stage III colon cancer. Some background Stage III colon cancer is cancer...

Read More

What is the preferred duration of post-operative chemotherapy for stage II and III colorectal cancer?

What is the preferred duration of post-operative chemotherapy for stage II and III colorectal cancer?

Posted by on Feb 24, 2013 in Colorectal cancer | 0 comments

Colorectal cancer (CRC) is one of the main causes of cancer related deaths. Patients diagnosed with CRC are treated with surgery to remove the tumor and affected tissue. If the tumor affects the entire thickness of the colon or rectal wall it is referred to as being stage II; if the local lymph nodes are also affected the cancer is referred to as being a...

Read More

The use of systemic chemotherapy for patients with poorly differentiated and signet cell adenocarcinoma of the appendix

The use of systemic chemotherapy for patients with poorly differentiated and signet cell adenocarcinoma of the appendix

Posted by on Feb 24, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study evaluated the effects of systemic chemotherapy and cytoreductive surgery (CRS) on survival in patients with aggressive types of cancer of the appendix (poorly differentiated and signet ring cell adenocarcinoma). The main findings were that systemic chemotherapy appears to be a viable treatment option for these types of...

Read More